CareDx, Inc. (NASDAQ:CDNA) Receives Consensus Recommendation of “Hold” from Analysts

CareDx, Inc. (NASDAQ:CDNA) has earned a consensus recommendation of “Hold” from the nine research firms that are currently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $26.00.

A number of equities analysts have commented on CDNA shares. Wall Street Zen lowered CareDx from a “hold” rating to a “sell” rating in a research note on Tuesday, October 28th. Weiss Ratings reissued a “sell (d+)” rating on shares of CareDx in a report on Wednesday, October 8th. Wells Fargo & Company dropped their target price on shares of CareDx from $19.00 to $14.00 and set an “equal weight” rating for the company in a research note on Friday, August 8th. BTIG Research upped their target price on shares of CareDx from $22.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, William Blair began coverage on shares of CareDx in a report on Tuesday, August 26th. They issued a “market perform” rating for the company.

Hedge Funds Weigh In On CareDx

Large investors have recently made changes to their positions in the company. MCF Advisors LLC increased its position in CareDx by 292.9% in the second quarter. MCF Advisors LLC now owns 1,336 shares of the company’s stock worth $26,000 after purchasing an additional 996 shares during the period. Allworth Financial LP bought a new position in shares of CareDx in the 2nd quarter valued at about $40,000. State of Alaska Department of Revenue acquired a new stake in shares of CareDx during the 3rd quarter worth approximately $43,000. PNC Financial Services Group Inc. boosted its stake in CareDx by 20,200.0% in the first quarter. PNC Financial Services Group Inc. now owns 4,466 shares of the company’s stock valued at $79,000 after acquiring an additional 4,444 shares during the last quarter. Finally, Morse Asset Management Inc bought a new stake in shares of CareDx during the 1st quarter valued at $103,000.

CareDx Stock Performance

CDNA opened at $15.01 on Friday. The firm has a market cap of $798.94 million, a price-to-earnings ratio of 14.72 and a beta of 2.50. The firm’s 50-day simple moving average is $14.49 and its 200-day simple moving average is $15.60. CareDx has a twelve month low of $10.96 and a twelve month high of $26.37.

CareDx (NASDAQ:CDNA) last announced its earnings results on Tuesday, November 4th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.13 by ($0.10). The business had revenue of $100.06 million during the quarter, compared to analyst estimates of $95.25 million. CareDx had a return on equity of 18.03% and a net margin of 17.97%.The firm’s revenue was up 20.7% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.14) earnings per share. CareDx has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that CareDx will post -0.9 EPS for the current fiscal year.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.